An­oth­er PhI­II RSV fail­ure thumps be­lea­guered No­vavax, but ex­ecs claim there's a way for­ward

Back in No­vem­ber 2016, when No­vavax was pick­ing up the scraps from a Phase III crash of its RSV vac­cine in old­er adults, the com­pa­ny point­ed to the Gates Foun­da­tion-backed pro­gram to test the vac­cine in in­fants as a “sig­nif­i­cant com­mer­cial op­por­tu­ni­ty.” It went on to be­come the lead pro­gram as No­vavax mount­ed an ar­du­ous come­back cam­paign for RSV-F vac­cine.

But to­day, ex­ecs con­ced­ed that the in­fant tri­al has suf­fered the same late-stage fate.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER